With multiple products for mono, sequential and continuous
combined needs,
view the MyWay HRT range AND availability below
| MONO FORMULATION OPTIONS (17ß ESTRADIOL) | |
|---|---|
|
Elleste™ Solo
Doses:
Elleste Solo™ MX
Doses:
|
|
Zumenon®
Doses:
|
|
SEQUENTIAL COMBINED FORMULATION OPTIONS (17ß ESTRADIOL + PROGESTIN) |
|
|---|---|
|
|
Elleste Duet™
Doses:
|
|
Femoston®
Doses:
|
|
CONTINUOUS COMBINED FORMULATION OPTIONS (17ß ESTRADIOL + PROGESTIN) |
|
|---|---|
|
|
Elleste Duet™ Conti
Doses:
|
|
|
Femoston® conti
Doses:
|
|
|
|
|
|
||
|---|---|---|---|---|---|
|
Forulaton options
|
Mono Formulations
|
Elleste™ Solo
Doses:
Elleste Solo™ MX
Doses:
|
Zumenon®
Doses:
|
||
|
Sequential Combined
17ß Estradiol+progestin |
Elleste Duet™
Doses:
|
Femoston®
Doses:
|
|||
|
Continuous Combined
17ß Estradiol + progestin |
Elleste Duet™ Conti
Doses:
|
Femoston® conti
Doses:
|
-
The Femoston® range of products contain both 17ß estrodiol and
dydrogesterone - The Femoston® range offers both sequential and continuous combined options
-
Dydrogesterone’s molecular structure and shape makes it a highly selective
progestin, binding almost exclusively to the progestogen receptors1 - In comparison to progesterone, dydrogesterone has increased bioavailability and has some progestogenic metabolites meaning that a dose of 10-20 times lower is adequate for endometrial proliferation1
Progestogen |
Progestogenic |
Oestrogenic |
Androgenic |
Anti-androgenic |
Glucocorticoid |
Anti- mineralo-corticoid |
|---|---|---|---|---|---|---|
| Progesterone | + | – | – | ± | + | + |
| Dydrogesterone | + | – | – | ± | – | ± |
| Drospirenone | + | – | – | + | – | + |
| MPA* | + | – | ± | – | + | – |
| Norethisterone | + | + | + | – | – | – |
| Levonorgestrel | + | – | + | – | – | – |
+ Effective; ± Weakly effective; – Not effective
*MPA: medroxyprogesterone acetate
| Receptors | Common side effects by stimulation of receptors |
|---|---|
| Oestrogenic | Breast tenderness, enlargement, leg cramps, bloating, nausea, headache |
| Progestogenic | PMS type symptoms, mood changes |
| Androgenic | Oily skin, acne, hirsutism |
| Glucocorticoid | Dosage and duration dependent: oedema, fluid retention, weight gain |
| Mineralcorticoid3 | Oedema, weight gain, bloating and migraine |
- Both the International Menopause Society (IMS) and the British Menopause Society (BMS) recommended that women should be placed on the lowest effective doses5,7
-
Some benefits of going low.6,7
- Provide adequate symptom relief
- Higher rates of amenorrhoea and better tolerability profile
- Less side effects and risk associated reduced progestogen required
- Patients to be more compliant, realising the benefits of HRT
- Can be used in new starters (if postmenopausal), ≥12 months since last period, long-term users and women who are considering weaning off
| Oestrogen | Ultra Low | Low | Standard | High |
|---|---|---|---|---|
| Conjugated equine oestrogens (mg) |
0.3 | 0.625 | 1.25 | |
| Micronized 17ß-oestradiol (mg) |
0.5 | 1 | 2 | 4 |
| Oestradiol valerate (mg) |
1 | 2 | ||
| Transdermal 17ß-oestradiol (μg) |
25 | 50 | 100 |
Table adapted from Maturitas, 40, Gambacciani M. Hormone replacement therapy: the benefits
in tailoring the regimen and dose. 195-201, Copyright (2001), with permission from Elsevier.
- Schindler AE. Maturitas 2003; 46(Suppl. 1): 7-16.
- Menopause matters, URL: https://www.menopausematters.co.uk/sideeffects.php.
- Jones EE. Am J Med 1995; 98(1A): 116S-9S.
- Panay N, et al. Human Reproduction Update 1997; 3( 2): 159-71.
- Baber RJ, et al. Climacteric 2016; 19(2): 109-50.
- Stevenson J, et al. Maturitas 2010; 67: 227-32.
- Panay N, et al. on behalf of the British Menopause Society (BMS) and Women’s Health Concern (WHC). Menopause International 2013; 19(2): 59-68.
HCP Disclaimer
This website is intended for healthcare professionals only.